Deep in a budget deal Congress passed earlier this year — just 118 words in Section 53116, a little before passages on prison reporting data and payment yields for seed cotton — was a hit to pharmaceutical companies that will cost them billions, and could signal more losses to come.
Despite an intense lobbying push, lawmakers changed a Medicare rule, putting manufacturers on the hook for more of seniors’ prescription costs. The companies will have to offer a much more generous discount to beneficiaries who fall into the so-called donut hole coverage gap, marking down retail costs by 70% instead of the current 50%.
It was a rare defeat for some of the biggest spenders in the political influence game and raised new questions about how they’ll fare in upcoming battles. Lawmakers have introduced bills that would squeeze the industry, and President Donald Trump has said he will roll out proposals this month to curb drug prices.
“They’re in a defensive position,” said Kim Monk, an analyst at Capital Alpha Partners in Washington. Investors are wondering, she said, if Big Pharma has lost its famed clout. That may be a stretch, but the pressure seems to be on. “I don’t see how they come out of this completely unscathed.”
Trump has gone on the rhetorical attack before, accusing drugmakers of “getting away with murder” and railing against prices he has called unjust. Now, though, he has promised to offer explicit solutions.
That could raise the stakes, said David Mitchell, president of the advocacy group Patients for Affordable Drugs. He’s been critical of Trump for failing to take action despite a lot of talk.
“If the president and administration threw its support behind a package of changes to prevent abuse it still will be a fight, but it would have a reasonable chance,” Mitchell said.
Secretary of Health and Human Services Alex Azar, a former Eli Lilly & Co. executive, has said there’s interest in doing more than lowering the bill for patients simply by having public and private insurers pick up larger shares of the tab; the retail prices that manufacturers set should just come down. Trump once suggested that Medicare should be allowed to directly negotiate what it pays for beneficiaries’ drugs.
Drug prices are largely unregulated in the U.S., and any plan to change that would need buy-in from antiregulation forces on Capitol Hill.
Meeting with reporters last month, Azar said the steps under consideration include regulatory actions, which he didn’t spell out, as well as “thoughts and requests for input” that could help crystallize what legislative measures the administration would support. He downplayed a recent Council of Economic Advisers report that basically blamed everyone except Big Pharma for spiraling prices, saying it was largely written before his confirmation in January.